Suraksha Diagnostic IPO subscribed overall 1.27 times on the last day, a retail quota was subscribed over 0.94 times, QIB was subscribed over 1.74 times, and NII was subscribed over 1.40 times respectively.
Details About Suraksha Diagnostic IPO
Suraksha Diagnostic got approval from SEBI for an IPO of ₹846.25 crores to raise funds and maintain financial stability. This IPO was entirely an Offer-for-sale of 1,91,89,330 equity shares with a face value of ₹2 each. Moreover, the company has set up a price band between ₹420 to ₹441 per share. In this IPO total of 34 shares were available in 1 lot size for the minimum Retail category. For the maximum retail category, a total of 442 shares were available in 13 lot sizes. For the S-HNI Minimum category total of 476 shares was available in 14 lot sizes. For the S-HNI Maximum category total of 2,244 shares were available in 66 lot sizes. While for B-HNI Minimum category total of 2,278 shares in 67 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Minimum Investors: An investment of ₹14,994 was required.
- Retail Maximum Investors: An investment of ₹1,94,922 was required.
- S-HNI Maximum: An investment of ₹2,09,916 was required.
- S-HNI Maximum: An investment of ₹9,89,604 was required.
- B-HNI Minimum: An investment of ₹1,004,598 was required.
Subscription duration of Suraksha Diagnostic IPO
This IPO started on November 29, 2024, and closed on December 3, 2024. The investor’s allotment date was December 4, 2024, and they received a refund on December 5, 2024.
Funds Deployment of This IPO
- To carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2 each aggregating to ₹ [●] million by the Selling Shareholders; and
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
About Suraksha Diagnostic Company
Suraksha Diagnostic was incorporated on 15 March 2005 and offers services like Medical testing, diagnostic solutions, and medical consultation. It is headquartered in East India and caters end-to-end solutions of pathology and radiology testing to its consumers through its functional network. Over time, it has collected various awards for identifying the brand’s awareness and focus in business. It has a good portfolio of over 2,300 tests including 788 pathology tests like basic biochemistry and haematology. 647 tests including advanced biochemistry, histopathology, and molecular pathology. In FY 2022 and 2024, the compounded annual growth rate(CAGR) of 20.87% in revenue and net income for FY 2024 was 23.13 crore. Furthermore, The leading diagnostic network with a strong presence in eastern India, outstanding profitability, and consistency in financial performance is a strength of this company. Due to its expertise have 1,522 permanent staff in the company.
Suraksha Diagnostic Company’s Financial Background
The company reported revenue of ₹218.71 crores in 2024 against ₹190.13 crores in 2023. The company reported Profit of ₹23.13 crores in 2024 against Profit of ₹6.07 crores in 2023.
